

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

---

(12) PATENT ABRIDGMENT (11) Document No. AU-B-75097/87  
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 610504

---

(54) Title  
ONE COMPONENT TISSUE ADHESIVE AND A PROCESS FOR THE PRODUCTION  
THEREOF

International Patent Classification(s)

(51) A61K 037/64 A61K 037/12 A61K 037/48

(21) Application No. : 75097/87 (22) Application Date : 03.07.87

(30) Priority Data

(31) Number (32) Date (33) Country  
3622642 05.07.86 DE FEDERAL REPUBLIC OF GERMANY

(43) Publication Date : 07.01.88

(44) Publication Date of Accepted Application : 23.06.91

(71) Applicant(s)  
BEHRINGWERKE AKTIENGESELLSCHAFT

(72) Inventor(s)  
NORBERT HEIMBURGER; PETER FUHGE; HANSJORG RONNEBERGER

(74) Attorney or Agent  
WATERMARK PATENT & TRADEMARK ATTORNEYS, Locked Bag 5, HAWTHORN VIC  
3122

(57) Claim

1. A tissue adhesive for treatment of wounds which coagulates after contact with a wound surface containing, in liquid or solid form, fibrinogen, F XIII, a thrombin inhibitor, prothrombin factors and calcium ions.

9. A process for the production of a tissue adhesive as claimed in Claim 1 or Claim 2, which comprises addition to an aqueous isotonic solution which has a pH of 7.5, which has been, where appropriate, pasteurized and, where appropriate, sterilized by filtration, and which contains at least 16 g/l human fibrinogen 2 g-atoms of calcium per mol of fibrinogen and 1-6 g/l L-arginine monohydrochloride, of sufficient of a solution, which has, where appropriate, been pasteurized of human factor XIII of human albumin, of prothrombin concentrate, of antithrombin III and of aprotinin and, where appropriate, Na glutamate and Isoleucine that the freeze-dried solution contains, after reconstitution in 1/4 of the volume dispensed into the container, these substances in the following concentration ranges:

65-115 mg/ml of human fibrinogen

40-80 U/ml of factor XIII

4-40 mg/ml of human albumin

1-50 IU/ml of PPSB (prothrombin factors) based on F II

(11) AU-B-75097/87

-2-

(10) 610504

(prothrombin)

0.01-50 IU/ml of antithrombin III

and where appropriate

1-10,000 KIU of aprotinin/ml

and 0.20 g/l of Na glutamate

and 0.20 g/l of isoleucine.

COMMONWEALTH OF AUSTRALIA  
PATENTS ACT 1962-68

66304<sup>10</sup>

# COMPLETE SPECIFICATION

(ORIGINAL)

Class


Int. Class

Application Number:  
Lodged:

Complete Specification Lodged:  
Accepted:  
Published:

Priority:

Related Art:



Name of Applicant: BEHRINGERWERKE AKTIENGESELLSCHAFT

Address of Applicant: D-3550 Marburg, Federal Republic of Germany

Actual Inventor: NORBERT HEIMBURGER, PETER FUHGE, HANSJORG RONNEBERGER

Address for Service: EDWD. WATERS & SONS,  
50 QUEEN STREET, MELBOURNE, AUSTRALIA, 3000.

Complete Specification for the invention entitled:

A ONE-COMPONENT TISSUE ADHESIVE AND A PROCESS FOR THE  
PRODUCTION THEREOF

The following statement is a full description of this invention, including the best method of performing it known to: US

Dr. Ha/Bn

A one-component tissue adhesive and a process for  
the production thereof

The invention relates to a tissue adhesive which contains fibrinogen, factor XIII, a thrombin inhibitor, prothrombin factors, calcium ions and, where appropriate, a plasmin inhibitor. The accelerators which are naturally present

5 on the wound which is to be bonded result in the thrombin which is necessary for adhesion being liberated from the prothrombin in the adhesive.

10 The physiological processes involved in the repair of lesions in human or animal tissues result in fibrin being deposited in the region of the injury. This is initiated by thromboplastin flowing out of the injured cells and, on contact with plasma factor VII forming factor X activator which then, together with factor V and in a complex

15 with phospholipids and calcium, converts prothrombin into thrombin. The action of thrombin in turn results, via elimination of the fibrinopeptides A and B from fibrinogen, in fibrin monomers which aggregate to form fibrin filaments which are covalently cross-linked, with the 20 formation of isopeptide bonds by F XIIIa, a transglutaminase which is likewise activated by thrombin. An inhibitor, namely alpha<sub>2</sub>-antiplasmin, is bound by factor XIII onto the fibrin filaments and protects them from degradation by plasmin.

25 It is evident from this process of hemostasis and wound healing that, in addition to fibrinogen as substrate, two enzymes are required: thrombin and factor XIII.

30 The task of thrombin in this connection is to activate both fibrinogen and factor XIII, that is to say to convert them into their reactive form. This is the fibrin

monomer in the case of fibrinogen, and is the catalytically active transglutaminase (F XIIIa) in the case of factor XIII.

5 European Patent 0,068,047 discloses an enriched plasma fraction which is suitable as a wound closure and contains fibrinogen, a fibrinolysis inhibitor and thrombin or prothrombin in an anhydrous system. This adhesive cannot be applied dissolved in water, but can be applied  
10 only as a powder, which is a disadvantage for use. When the mixture is dissolved in water, the components react together, and a clot is produced.

For a one-component adhesive with water as solvent it is  
15 difficult to combine the active substances in such a way and in such quantitative ratios that no premature and undesired activation takes place during the production of the adhesive, the reconstitution with a solvent and the maintenance in readiness for use and, on the other hand,  
20 a sufficiently high strength is achieved relatively quickly after application to the adhesion site.

Surprisingly, conditions allowing reproducible production  
25 of a one-component adhesive, which can be manipulated in practice, in a physiological medium have been found.

The requirements for a one-component adhesive of this type to be produced and be amenable to processing are that the relative concentrations of fibrinogen, plasmin  
30 inhibitor, F XIII, prothrombin concentrate, thrombin inhibitor and calcium ions are optimized. This particularly applies to AT III as thrombin inhibitor and to calcium ions, since the calcium ions are essential for activation of the coagulation factors. High concentrations increase  
35 the rate of thrombin formation, and low concentrations slow it down. Hence it is necessary that the concentration of calcium ions is optimal. Since, when this is the case, the formation of thrombin cannot be ruled out, it is expedient to combine with a thrombin inhibitor,

preferably AT III. This is because, on the one hand, the formation of thrombin must be ruled out during the production of the adhesive and, on the other hand, the adhesive must rapidly form a stable clot when coagulation, that is to say the deposition of a fibrin film, is initiated on contact with wound surfaces. Accordingly, the production of a

5 thrombin-containing one-component adhesive and its use in aqueous solution is inconceivable and, moreover, it is possible to use prothrombin only under conditions which prevent activation to thrombin during production and preparation for use. These include setting up defined concentration for use. These include setting up defined concentrations of thrombin inhibitor and calcium ions.

10 Thus the invention relates to a tissue adhesive which coagulates after contact with a wound surface containing in liquid or solid form fibrinogen, F XIII, a thrombin inhibitor, prothrombin factors, calcium ions and, where appropriate, a plasmin inhibitor.

15 The invention also relates to a method of preparation of the tissue adhesive.

It was surprising that it is possible to pack, and use as tissue adhesive, fibrinogen together with prothrombin as a so-called hypercoagulable solution which, moreover also contains calcium ions and AT III.

20 An adhesive of this type according to the invention can be converted into a solid form, for example freeze-dried, and reconstituted with water. It can contain all the active substances in pasteurized form, and is then free of the risk of transmission of hepatitis and HTLV III.

25 The mixing ratio of the active substances fibrinogen, plasmin inhibitor, F XIII, prothrombin factors, calcium ions and AT III is such that no premature activation takes place and such that, however, the mixture spontaneously coagulates, and deposits fibrin, on contact with wound surfaces.

The time in which this takes place is consistent with clinical requirements. The one-component adhesive

30



according to the invention does not differ in its action from the two-component systems of the state of the art.

The mixture of active substances in this adhesive is such that, in the solution for use, the concentration of fibrinogen is 70-90 mg/ml and that of the prothrombin factors is between 10 and 30 U/ml based on F II. The concentration of calcium ions, some of which are protein-bound in the adhesive, is intended to be 0.5-1 mmol/l in the solution for use. Examples of thrombin inhibitors are AT III, hirudin and heparin, and AT III is preferably used in a concentration of 0.1-1 U/ml of tissue adhesive; at this concentration it prevents, at the abovementioned concentrations of prothrombin factors and calcium ions, premature fibrin formation. On the other hand, however, it is possible to favor the latter when this appears desirable on the basis of the indication. For this purpose, it is possible to dissolve the freeze-dried adhesive in a higher final concentration of calcium ions than 0.5-1 mmol/l. However, rapid use after reconstitution is then necessary.

To produce the adhesive, the active substances are initially produced in soluble form having the highest possible activity and, where appropriate, having been pasteurized. The fibrinogen concentration should be as high as possible, since the strength of adhesion increases with increasing concentration. The fibrinogen can, for example, be produced and pasteurized as described in European Patent 0,103,196, and given the desired solubility by additives of the type of compound containing urea or guanidine residues as described in European Patent 0,085,923. Factor XIII can be pasteurized as described in European Patent 0,018,561, and the prothrombin factors can be pasteurized as described in European Patent 0,056,629.

The active substances in the preferred adhesive according to the invention in principle comprise human fibrinogen

in the highest possible concentration, enriched with factor XIII and the factors of the prothrombin complex (factor II, VII, IX and X), calcium ions and antithrombin III. The tissue adhesive also contains an inhibitor 5 which inhibits plasminogen activators and/or plasmin and thus protects the resulting fibrin from degradation by plasmin. This inhibitor may be in the form of a concomitant substance of the fibrinogen selected for the bonding, but is preferably added to the adhesive in the form 10 of aprotinin. To improve the reconstitution of the tissue adhesive after freeze-drying, it is possible for the latter to contain albumin and/or substances which contain the urea or guanidine residue and also contain, where appropriate, an amino acid with a hydrophobic side-chain 15 or a water-soluble fatty acid and, in addition, heparin.

The fibrinogen which is suitable and preferred for preparation of the tissue adhesive is purified and already contains factor XIII. However, apart from this, also 20 suitable is cryoprecipitate which, experience has shown, contains alpha<sub>2</sub>-antiplasmin and human albumin in addition to factor XIII. It is also possible, however, to produce an adhesive of comparable action by mixing the individual components, namely: human fibrinogen, factor 25 XIII (from plasma or placenta), plasmin inhibitors, prothrombin factors (factor II, VII, IX and X), albumin, AT III and calcium ions, a compound with a urea or guanidine residue, or an amino acid with a hydrophobic side-chain or a water-soluble fatty acid.

30 The mixture of the active compounds for the adhesive is advantageously in the form of a solid, preferably a lyophilizate.

35 The tissue adhesive preferably contains the following quantities of active compounds, which are pasteurized where appropriate, based on 1 ml of solution for use:

65 - 115, preferably 70 - 90, mg of highly purified human

fibrinogen

40 - 80 U of factor XIII

1 - 50, preferably 10 - 30, IU of PPSB (prothrombin factors) based on F II (prothrombin)

5 C - 10,000 KIU of aprotinin

0.01 - 50, preferably 0.1 - 1, IU of antithrombin III

0 - 5 USP U heparin and

0.1 - 5, preferably 0.5 - 1 mmol/lofcalcium ions, preferably as calcium chloride.

10

The adhesive can contain, for example glutamate, L-isoleucine, L-arginine or human albumin as stabilizers and solubilizers.

15

The mixture of the solid active compounds of the tissue adhesive can be dissolved in water, or in a solvent containing calcium ions, in a short time at 20°C. When applied to the tissue which is to be united or bonded the adhesive develops within a sufficiently short time a high bonding strength without thrombin being necessary as a second component.

20

Accordingly, it is possible to apply the adhesive in liquid form using a single syringe, so that preparation, manipulation and use are straightforward. The adhesive is tolerated and is completely absorbed.

25

This one-component adhesive does not differ, either in the bonding time or in the rupture strength, from a two-component adhesive, as has been found in bonding tests in the model of puncture wounds of the rat skin and in the bonding of small intestinal anastomoses in hogs. It is even possible to increase the bonding strength by choosing an optimal calcium ion concentration of the solution which is used to dissolve the freeze-dried active compounds.

The examples which follow are intended to illustrate the invention.

Example 1

To produce 500 ml of tissue adhesive, 580 g of pasteurized highly purified human fibrinogen which contained 2 calcium ions per mole and had been obtained as described in European Patent 0,103,196 were dissolved in 580 ml of buffer, pH 7.5 (dialysis buffer), with the following composition:

5 0.05 mol/l NaCl  
10 0.005 mol/l trisodium citrate  
15 0.3 g/100 ml L-arginine monohydrochloride.

The fibrinogen solution which had been obtained in this way was dialysed twice for 16 hours and once for 8 hours, 15 in each case against 36 l of buffer of the same composition, at +4°C. The volume of the fibrinogen solution after the dialysis was 1.53 l. The solution was then centrifuged at 8000 x g for 20 min. The optical density of the solution, measured at 280 nm, was 47. This solution 20 was diluted with the abovementioned buffer, to which the other adhesive components had been added (see below), to an optical density (280 nm) of 35 to 37, i.e. to about 20 g/l human fibrinogen.

25 The specific procedure for this was as follows: the dialysed and centrifuged human fibrinogen solution (1.53 l) was filtered successively through filters of pore sizes 0.65 and 0.2  $\mu$  at 35 to 37°C. 117.5 ml of pasteurized F XIII concentrate, containing 350 U of F XIII/ml of physiological saline solution, was filtered through a filter of 0.2  $\mu$  pore size into the resulting sterile fibrinogen solution.

35 Then 515,000 KIU (kallikrein inhibitor units) of aprotinin, 5.13 g of Na glutamate, 33.9 ml of a human albumin solution containing 20 g/100 ml, 6.78 g of isoleucine and 10,000 U of pasteurized PPSB concentrate (prothrombin factor concentrate; activity in units based on F II), 100 U of AT III (pasteurized) and 3.1 ml of 0.1 mol/l  $\text{CaCl}_2$

solution were added.

The volume was then made up to 407.5 ml with dialysis buffer. This solution was filtered through a filter of 5 0.2  $\mu$  pore size into the F XIII-containing fibrinogen solution. About 2,055 ml of solution of pH 7.5 and the following composition were obtained:

|    |                   |         |                          |
|----|-------------------|---------|--------------------------|
|    | human fibrinogen  | 2.0     | g/100 ml                 |
| 10 | human albumin     | 0.33    | g/100 ml                 |
|    | arginine          | 0.3     | g/100 ml                 |
|    | Na glutamate      | 2.5     | g/l                      |
|    | isoleucine        | 3.3     | g/l                      |
|    | factor XIII       | 20,000  | U/l                      |
| 15 | aprotinin         | 250,000 | KIU/l                    |
|    | prothrombin       | 5,000   | U/l (calculated as F II) |
|    | antithrombin III  | 50      | U/l                      |
|    | NaCl              | 0.05    | mol/l                    |
|    | trisodium citrate | 0.005   | mol/l                    |
| 20 | calcium chloride  | 0.15    | mmol/l.                  |

The sterile solution was packed in 4 ml portions and freeze-dried. A colorless, rapidly dissolving lyophili-  
zate was obtained.

25

For use as tissue adhesive, one packed portion was taken up in 1 ml of solvent.

### Example 2

30

To produce 125 ml of tissue adhesive, 100 g of a pasteur-  
ized, highly purified human fibrinogen fraction, obtained  
as described in European Patent 0,103,196, were dis-  
solved in 112 ml of dialysis buffer and dialyzed three  
35 times against 10 l each time of the same buffer as  
in Example 1. The volume of the concentrated fibrinogen  
solution after dialysis was 269 ml. It was centrifuged  
at 8,000  $\times$  g for 20 min. The optical density of the solu-  
tion at 280 nm was 69.2. The solution was diluted with

8 buffer whose composition corresponds to that of the dialysis buffer, and in which all the other adhesive components have been mixed, in such a way that an optical density at 280 nm of 35 - 37, based on fibrinogen, was  
5 reached.

The procedure for this was as follows:

127 ml of buffer were introduced into a vessel and then  
8.2 ml of human albumin solution containing 20 g of human  
10 albumin per 100 ml of solution, 6 ml aprotinin amounting  
to 125,000 KIU and 50 ml of prothrombin concentrate con-  
taining 2,500 U of factor II and 25 U of AT III were  
added. 1.65 g of L-isoleucine and 1.25 g of Na glutamate  
were dissolved in this, and then 40 ml of F XIII concen-  
trate containing 10,000 U of F XIII were added, the mix-  
ture was homogenized, and the pH of the solution was ad-  
justed to pH 7.5.

Subsequently this solution was mixed and homogenized with  
20 the fibrinogen solution which is described above and 0.75  
ml of a 0.1 molar  $\text{CaCl}_2$  solution, and was sterilized  
by filtration through a filter of pore size 0.2  $\mu$  at 35-  
37°C. About 500 ml of sterile solution of the composi-  
tion as in Example 1 were obtained. This solution was  
25 packed in 4 ml quantities and freeze-dried. A colorless,  
rapidly dissolving lyophilizate was obtained.

For use as tissue adhesive, one packed portion is taken up  
in 1 ml of solvent.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A tissue adhesive for treatment of wounds which coagulates after contact with a wound surface containing, in liquid or solid form, fibrinogen, F xiii, a thrombin inhibitor, prothrombin factors and calcium ions.
2. A tissue of Claim 1 which contains a plasmin inhibitor.
3. A tissue adhesive as claimed in Claim 1 or Claim 2 which is in the form of a solid.
4. A tissue adhesive as claimed in any one of Claims 1 to 3 wherein all the active substances it contains are pasteurized.
5. A tissue adhesive as claimed in any one of Claims 1 to 4 which contains in solution 70-90 mg/ml fibrinogen, 10-30 U/ml (based on F xii) prothrombin factors, 0.5-1 mmol/l calcium ions and 0.1-1 IU/ml AT III.
6. A tissue adhesive as claimed in any one of Claims 1 to 5 which contains as plasmin inhibitor aprotinin or alpha<sub>2</sub>-anti-plasmin.
7. A tissue adhesive as claimed in any one of Claims 1 to 6 which contains as thrombin inhibitor antithrombin III, hirudin or heparin.
8. A tissue adhesive as claimed in any one of Claims 1 to 7 which contains in 1 ml of solution  
65-115 mg of human fibrinogen  
40-80 U of factor xiii  
1-50 IU of PPSB (prothrombin factors) based on F xii (prothrombin)  
0.01-50 IU of antithrombin III  
0.1-5 mmol/l of calcium ions  
and where appropriate  
1-10,000 KIU of aprotinin.



9. A process for the production of a tissue adhesive as claimed in Claim 1 or Claim 2, which comprises addition to an aqueous isotonic solution which has a pH of 7.5, which has been, where appropriate, pasteurized and, where appropriate, sterilized by filtration, and which contains at least 16 g/l human fibrinogen 2 g-atoms of calcium per mol of fibrinogen and 1.6 g/l L-arginine monohydrochloride, of sufficient of a solution, which has, where appropriate, been pasteurized of human factor XIII of human albumin, of prothrombin concentrate, of antithrombin III and of aprotinin and, where appropriate, Na glutamate and Isoleucine that the freeze-dried solution contains, after reconstitution in 1/4 of the volume dispensed into the container, those substances in the following concentration ranges:

65-115 mg/ml of human fibrinogen

40-80 U/ml of factor XIII

4-40 mg/ml of human albumin

1-50 IU/ml of PPSB (prothrombin factors) based on F II  
(prothrombin)

0.01-50 IU/ml of antithrombin III

and where appropriate

1-10,000 KIU of aprotinin/ml

and 0.20 g/l of Na glutamate

and 0.20 g/l of Isoleucine.

DATED this 21st day of February, 1991

BEHRINGWERKE AKTIENGESELLSCHAFT

**WATERMARK PATENT & TRADEMARK ATTORNEYS**

**2nd Floor, "The Atrium"**

**290 Burwood Road, Hawthorn**

**VICTORIA, 3122**

**AUSTRALIA**

**DBM/JMW:JJC**

